v3.26.1
NET LOSS PER SHARE
12 Months Ended
Dec. 31, 2025
NET LOSS PER SHARE  
NET LOSS PER SHARE

13.      NET LOSS PER SHARE

As of December 31, 2025, 2024, and 2023, outstanding share options totaling 3,083,414, 3,574,453 and 4,055,164, respectively, were anti-dilutive, and therefore, were not included in the computation of weighted average shares used in computing diluted loss per share. As of December 31, 2025, the Company had 1,000,000 pre-funded warrants issued in connection with the PIPE Transaction that are exercisable at any time for nominal cash consideration. These pre-funded warrants were included in the denominator for basic and diluted net loss per share.

The following table sets forth the basic and diluted net loss per share computation and provides a reconciliation of the numerator and denominator for the periods presented:

 

Year Ended December 31,

(In thousands, except share and per share data)

  ​ ​ ​

2025

  ​ ​ ​

2024

  ​ ​ ​

2023

Numerator:

  ​

  ​ ​ ​

Net loss attributable to CASI Pharmaceuticals, Inc.

$

(48,058)

$

(39,258)

$

(26,960)

Denominator:

 

  ​

  ​

Weighted-average shares outstanding used in computing net loss per share, basic and diluted

 

18,538,046

 

15,340,277

 

13,360,185

Denominator for basic and diluted net loss per share calculation

 

18,538,046

 

15,340,277

 

13,360,185

Net loss per share

 

  ​

  ​

— Basic and diluted

$

(2.59)

$

(2.56)

$

(2.02)